News

Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease
Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS ...
EconoTimes59m
FDA Expands Moderna’s RSV Vaccine Use to At-Risk Adults Aged 18–59
The U.S. Food and Drug Administration (FDA) has expanded the use of Modernas (NASDAQ:MRNA) RSV vaccine, mRESVIA, to adults aged 18 to 59 who are at increased risk of respiratory syncytial virus (RSV) ...